Sugi Predict

Sugi Predict / Compounds / SCHEMBL793493

SCHEMBL793493

SCHEMBL793493

O=C1NCCc2ccc(Cl)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 10/20 1.00
▸ PARP1 P09874 6/20 1.00
▸ F7 P08709 1/20 1.00
▸ F3 P13726 1/20 1.00
▸ PARP11 Q9NR21 6/20 0.56
▸ PDPK1 O15530 1/20 0.56
▸ GRM5 P41594 3/20 0.52
▸ JAK2 O60674 1/20 0.51
▸ NTRK1 P04629 1/20 0.51
▸ MET P08581 1/20 0.51
▸ FGFR1 P11362 1/20 0.51
▸ PRKACA P17612 1/20 0.51
▸ KDR P35968 1/20 0.51
▸ MAP2K2 P36507 1/20 0.51
▸ FLT3 P36888 1/20 0.51
▸ GSK3B P49841 1/20 0.51
▸ MAP2K1 Q02750 1/20 0.51
▸ MST1R Q04912 1/20 0.51
▸ NTRK3 Q16288 1/20 0.51
▸ NTRK2 Q16620 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29676942 1.00 PARP10 (1.00) PARP10PARP1F7F3PARP11
SCHEMBL31743097 0.89 PARP10 (0.81) PARP10PARP1F7F3PARP11
SCHEMBL19838574 0.89 PARP10 (0.81) PARP10PARP1F7F3PARP11
SCHEMBL1315035 0.85 PARP10 (0.74) PARP10PARP1F7F3PARP11
SCHEMBL30454034 0.82 PARP10 (0.68) PARP10PARP1F7F3PARP11
SCHEMBL22391640 0.82 PARP10 (0.68) PARP10PARP1F7F3PARP11
SCHEMBL1760377 0.81 NTRK2 (0.74) PARP10PARP1F7F3JAK2
SCHEMBL1952863 0.80 PARP10 (0.65) PARP10PARP1F7F3PARP11
SCHEMBL17750046 0.80 PARP10 (0.67) PARP10PARP1F7F3PARP11
SCHEMBL23952279 0.78 PARP10 (1.00) PARP10PARP1F7F3PARP11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368136-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-11-07 — — US disclosed
EP-3365334-B1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMA CO LTD (JP) 2024-07-17 — — EP disclosed
EP-3365334-B1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMA CO LTD (JP) 2024-07-17 — — EP disclosed
US-11939321-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-03-26 — — US disclosed
WO-2023237078-A1 ISOQUINOLINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND USE THEREOF 拜西欧斯（北京）生物技术有限公司 2023-12-14 — — WO disclosed
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 — — US disclosed
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 — — US disclosed
CN-114948963-A Protein kinase inhibitor benzolactam compounds 大冢制药株式会社 2022-08-30 — — CN disclosed
CN-108617166-B Protein kinase inhibitor benzolactam compounds 大冢制药株式会社 2022-05-17 — — CN disclosed
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-05-11 — — US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 — — US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 — — US disclosed
EP-2627648-A1 17aHYDROXYLASE/C17,20-LYASE INHIBITORS Novartis AG (CH) 2013-08-21 — — EP disclosed
WO-2012035078-A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 — — WO disclosed
WO-2012035078-A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 — — WO disclosed
US-20030158218-A1 Thrombin inhibitors NANTERMET PHILIPPE G (US) 2003-08-21 — — US disclosed
US-6515011-B2 Anticoagulants MERCK & CO., INC. 2003-02-04 — — US disclosed
US-20020119992-A1 Thrombin inhibitors MERCK & CO., INC. 2002-08-29 — — US disclosed
WO-2002057225-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-07-25 — — WO disclosed
WO-2002050056-A1 BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939321-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 PARP10 3558/4885PARP1 1718/4885F7 3341/4885
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 PARP10 3558/4885PARP1 1718/4885F7 3341/4885
US-20020119992-A1 Thrombin inhibitors SERPINC1, F2, TFPI PARP10 414/4885PARP1 862/4885F7 43/4885
US-20030158218-A1 Thrombin inhibitors F2, SERPINC1, TFPI PARP10 376/4885PARP1 313/4885F7 43/4885
US-20240368136-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 PARP10 3573/4885PARP1 1722/4885F7 3284/4885
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 PARP10 3734/4885PARP1 1877/4885F7 3056/4885
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 PARP10 940/4885PARP1 2549/4885F7 2639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.